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Summary
Previously, our laboratory demonstrated the existence of a β-subunit glycosylation-deficient 
human FSH glycoform, hFSH21. A third variant, hFSH18, has recently been detected in FSH 
glycoforms isolated from purified pituitary hLH preparations. Human FSH21 abundance in 
individual female pituitaries progressively decreased with increasing age. Hypo-glycosylated 
glycoform preparations are significantly more active than fully-glycosylated hFSH preparations. 
The purpose of this study was to produce, purify and chemically characterize both glycoform 
variants expressed by a mammalian cell line. Recombinant hFSH was expressed in a stable GH3 
cell line and isolated from serum-free cell culture medium by sequential, hydrophobic and 
immunoaffinity chromatography. FSH glycoform fractions were separated by Superdex 75 gel-
filtration. Western blot analysis revealed the presence of both hFSH18 and hFSH21 glycoforms in 
the low molecular weight fraction, however, their electrophoretic mobilities differed from those 
associated with the corresponding pituitary hFSH variants. Edman degradation of FSH21/18 -
derived β-subunit before and after peptide-N-glycanase F digestion confirmed that it possessed a 
mixture of both mono-glycosylated FSHβ subunits, as both Asn7 and Asn24 were partially 
glycosylated. FSH receptor-binding assays confirmed our previous observations that hFSH21/18 
exhibits greater receptor-binding affinity and occupies more FSH binding sites when compared to 
fully-glycosylated hFSH24. Thus, the age-related reduction in hypo-glycosylated hFSH 
significantly reduces circulating levels of FSH biological activity that may further compromise 
reproductive function. Taken together, the ability to express and isolate recombinant hFSH 
glycoforms opens the way to study functional differences between them both in vivo and in vitro.
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1. Introduction
Human pituitary FSH consists of three or four major glycoforms that differ in glycosylation 
of the hormone-specific β–subunit (Bousfield et al., 2008, Bousfield et al., 2014a, Bousfield 
et al., 2007, Walton et al., 2001). Fully glycosylated FSHβ subunit is detected in FSHβ-
specific Western blots as a 24,000 Mr band, while two glycan-deficient forms have been 
described, one that appears as a 21,000 Mr band (Walton et al., 2001) and another that is 
characterized by an 18,000 Mr band (Bousfield et al., 2014a). A non-glycosylated hFSHβ 
was detected by mass spectrometry (Bousfield et al., 2008, Bousfield et al., 2007, Walton et 
al., 2001), but in Western blots the 15,000 Mr hFSHβ band has only been observed after 
peptide-N-glycanase F (PNGase F) treatment of the other glycoforms (Bousfield et al., 
2014a). Most pituitary and urinary hFSH preparations we have analyzed possess both Mr 
24,000 (FSHβ24) and Mr 21,000 (FSHβ21) β-subunit variants, although the ratios may differ 
(Bousfield et al., 2008, Bousfield et al., 2014a, Bousfield et al., 2007, Walton et al., 2001). 
For simplicity, the hFSH glycoform with FSHβ24 will be designated as hFSH24, the one with 
FSHβ21 as hFSH21, and the one with FSHβ18 as hFSH18. Mixtures of glycoforms, such as 
pituitary hFSH, which possesses more FSHβ24 than FSHβ21, will be designated as 
hFSH24/21, with the first number indicating the more abundant variant. In our previous 
publications, we referred to hFSH21 as “di-glycosylated”, as mass spectrometry and Edman 
degradation independently demonstrated that the original FSHβ21 subunit preparation lacked 
both N-glycans (Walton et al., 2001). Thus, only the α subunit possessed N-glycans. Human 
FSH24 was termed “tetra-glycosylated” hFSH to indicate dual N-glycosylation of both α and 
β subunits (Bousfield et al., 2008, Bousfield et al., 2014a, Bousfield et al., 2007, Walton et 
al., 2001). Transgenic mice also express a non-glycosylated FSHβ15, which can 
heterodimerize with the mouse α-subunit to form hFSH15, however, it appears to be retained 
by pituitary gonadotropes (Davis et al., 2014).
The relative abundance of hFSH21 in individual female pituitaries appears to be dependent 
on the age of the woman and to decrease over reproductive life. The ratio of hFSH21/
hFSH24 in the pituitary changed from hFSH21 -dominant in 21- to 24-year old women to 
roughly equivalent in 39- to 41-year old women to hFSH24 -dominant in 55- to 81-year old 
women (Bousfield et al., 2014b). Increased abundance of high molecular weight forms of 
pituitary FSH followed ovariectomy in both rhesus macaque and rat females (Bogdanove, 
Campbell and Peckham, 1974, Peckham et al., 1973). Sephadex G-100 chromatograms 
indicated 56% ovariectomized rhesus pituitary hFSH was the high molecular weight variant 
(Peckham and Knobil, 1976). Western blots of individual ovariectomized rhesus pituitary 
FSH samples revealed 57% was FSH24 (Bousfield et al., 2007). Estrogen replacement in 
ovariectomized females reduced the abundance of high molecular weight FSH (Bogdanove 
et al., 1974, Peckham and Knobil, 1976). Neuraminidase digestion of rhesus FSH from 
ovariectomized females also reduced the abundance of high molecular weight FSH, which 
suggested the increase in size was due to sialic acid (Peckham and Knobil, 1976). It is not 
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yet clear what ovarian factor(s) regulate human FSH glycoform abundance. For example, 
the shift from hFSH21-dominant to hFSH21/hFSH24 equivalent ratios preceded the age at 
which circulating estrogen is known to decrease (Randolph et al., 2011).
Since both glycoforms were also present in the urine of women (Bousfield et al., 2014b), 
they were secreted by the pituitary into the circulation, where they can influence ovarian 
activity. Possibly, the glycoform ratios in the blood change over time and exacerbate 
declining function of the aging ovary by limited cellular activation via the FSH receptor. We 
recently reported that pituitary hFSH21/18 exhibited a 9- to 20-fold higher hFSH receptor-
binding activity and occupied twice as many receptors as hFSH24 (Bousfield et al., 2014a). 
Urinary hFSH preparations used in assisted reproduction represent mostly hFSH24 
(Bousfield et al., 2007), since they are purified from postmenopausal urine. Most of the 
recombinant hFSH preparations commercially available for use in ovarian stimulation for 
assisted reproduction, such as Gonal F, consist largely of the hFSH24 glycoform (see below). 
Therefore, it would be interesting to see if the hFSH21 or hFSH18 glycoforms are beneficial 
for assisted reproduction procedures.
A randomized, open-label clinical study performed on 188 infertile couples reported that 
two types of hFSH preparations with different glycosylation patterns had different impacts 
on oocyte quality and clinical outcome (Selman H, 2010). A sequential combined protocol 
using both acidic and less-acidic hFSH preparations for ovarian stimulation improved oocyte 
maturity, implantation, and pregnancy rates (Selman H, 2010). Another possible practical 
application is a development of a monoclonal antibody specific only to hFSH21 or hFSH18 
glycoforms (in progress in our laboratory).
The aim of this study was to produce, isolate and structurally characterize recombinant 
hFSH glycoforms, to be used in the future for further in vitro and in vivo characterization of 
FSH action.
2. Materials and Methods
2.1 Hormone Preparations
Recombinant hFSH preparations, Follistim and GonalF were obtained from Organon and 
Serono, respectively. Purified pituitary hFSH preparations AFP-4161, AFP-5720D, and 
AFP-7298A were obtained from the National Hormone and Pituitary Program. Urinary 
hFSH was purchased from ProSpec, East Brunswick, NJ. Human pituitary FSH glycoforms 
were prepared as described previously (Bousfield et al., 2014a). Recombinant GH3-
hFSH24/21 was purified from small samples of conditioned medium by the same procedure 
used to isolate pituitary hFSH21/18; monoclonal antibody 46.3H6.B7 immunoaffinity 
chromatography followed by Superdex 75 gel filtration (Bousfield et al., 2014a). Antibodies 
used in this study are listed in supplement Table 1.
2.2 Analytical Procedures
Details of all procedures can be found in the supplement to this article. SDS-PAGE 
(Laemmli, 1970) was carried out using a Bio-Rad (Hercules, CA) Protean III mini-gel 
apparatus (Bousfield et al., 2007). Conventional Western blots of PVDF membranes were 
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carried out as previously described (Bousfield et al., 2014a). Automated Western blot 
procedures were carried out using a ProteinSimple (Santa Clara, CA) Simon following the 
manufacturer’s recommendations. Nano-electrospray ionization mass spectrometry was 
carried out as recently described for pituitary and urinary hFSH samples (Bousfield et al., 
2014b). Carbohydrate composition analysis was carried out on 4 N TFA hydrolysates 
(Bousfield et al., 2000) using a Thermo Scientific Dionex (Sunnyvale, CA) ISC-5000 
carbohydrate analyzer. FSHβ glycosylation sites were analyzed by a combination of 
PNGaseF digestion and automated Edman degradation. Glycosyltransferase expression was 
detected by RT-PCR.
2.3 Large-scale Recombinant hFSH Purification
Details of recombinant GH3-hFSH expression and glycoform purification can be found in 
the supplement. A rat pituitary tumor GH3 cell line, stably transfected with hFSH α- and β-
subunits (Muyan, Ryzmkiewicz and Boime, 1994), was the generous gift of Dr. I. Boime 
(Washington University Medical School, St. Louis, MO). Culture medium conditioned by 
these cells was the source of recombinant hFSH. The hormone was captured from 10.4 L 
serum-free culture medium by Octyl-Sepharose chromatography, then immunopurified with 
immobilized monoclonal antibody 4882 (SPD Development Co., Ltd., Bedford, UK.), which 
recognizes an α-subunit epitope and captures all human glycoprotein hormones. 
Immunopurified hFSH was fractionated by gel filtration using three, 10 X 300 mm Superdex 
75 (GE Healthcare, Piscataway, NJ) columns, connected in series. Relative glycoform 
abundance was determined by Western blot and the appropriate fractions pooled.
2.4 FSH receptor-binding assays
Animal procedures were approved by an institutional animal care and use committee. 
Competitive binding assays were carried out as described previously (Butnev et al., 1996). 
Saturation binding assays were carried out as described previously (Bousfield et al., 2014a) 
except bovine (Dias, Huston and Reichert, 1981) and human (Butnev et al., 1998) FSH 
receptor preparations were included.
3. Results
3.1 GH3-hFSH glycoform abundance
Western blot analysis of samples from small-scale expression experiments suggested 
recombinant hFSH expressed by GH3 cells might provide a more abundant source of 
partially glycosylated FSH glycoforms than pituitary extracts and commercially available 
recombinant hFSH preparations (Fig. 1). The relative abundance of the FSHβ21 band 
averaged 55% in mAb 46.3H6.B7 immunoaffinity/Superdex 75 gel filtration-purified, 
recombinant hFSH samples recovered from GH3 cells grown in 100 mm culture dishes (Fig. 
1, lanes 2 and 3). This was greater than the 20–27% abundance found in pituitary and 
recombinant hFSH preparations (Fig. 1, lanes 4 and 7–10). GonalF revealed a triplet of 
immunoreactive bands in the FSHβ21 region of the gel, instead of the broad, glycoprotein-
like band observed in pituitary FSH preparations. All the pituitary FSHα subunit bands 
migrated faster than commercially produced recombinant hFSHα subunits (compare lower 
panel lanes 4–6 with 7–10).
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3.2 Characterization of total GH3-hFSH glycans by nano-spray mass spectrometry
Pituitary and recombinant hFSH oligosaccharide microheterogeneity was compared to 
identify differences in N-glycan populations that might impact biological activity. PNGaseF 
digestion quantitatively released oligosaccharides from reduced, carboxymethylated GH3-
hFSH, as indicated by a shift to later retention time for the PNGaseF-digested hormone 
sample (data not shown). The PNGaseF-released oligosaccharides were analyzed by nano-
spray mass spectrometry as described in supplementary materials. The spectra (supplement 
Fig. 2) were relatively weak compared with those from the pituitary hFSH and hFSH 
glycoform samples analyzed at the same time (Bousfield et al., 2014a); consequently, some 
minor glycans may have been missed. The glycans were predominantly bi- and tri-antennary 
complex-type oligosaccharides (supplement Fig. 3 and supplement Table 3), with the bi-
antennary more abundant than the tri-antennary (Fig. 2A), the opposite of what was 
encountered with the pituitary hFSH preparation and with reports in the literature (Green 
and Baenziger, 1988a, b, Renwick et al., 1987). A small amount of tetra-antennary structures 
may have been present but fragmentation spectra of these minor ions (supplement Table 3) 
were not obtained and, consequently, the possibility that these ions were from tri-antennary 
glycans with N-acetyl-lactosamine extensions cannot be excluded. Unlike pituitary hFSH 
samples, the tri-antennary glycans possessed 2 branches on the 6-antenna instead of the 3-
antenna (Harvey et al., 2008). Both neutral and acidic glycans were present; the acidic 
groups were all Neu5Ac, no sulfate was detected. The glycans also contained a substantial 
amount of fucose on the antennae, unlike the glycans from pituitary hFSH.
Of the four most abundant pituitary glycan families, based on neutral core oligosaccharide 
structure, two were triantennary, two were biantennary, and together they accounted for 
almost 40% of the glycan families (Fig. 2A and B), while three of the 4 most abundant 
recombinant hFSH glycans were biantennary, only one was triantennary. Together, these 
added up to just over 50%. The three most abundant individual glycan structures in both 
preparations were di-sialylated biantennary glycans (Fig. 2C and D), while the fourth was 
tri-sialylated, triantennary for pituitary hFSH and fucosylated, tri-sialylated, triantennary for 
recombinant hFSH. The four most abundant glycans accounted for 30% and 36% of the 
pituitary and recombinant hFSH glycans, respectively. Overall, recombinant hFSH glycans 
were less diverse than in pituitary hFSH, possessed relatively fewer large glycans of the 
triantennary class, and appeared to completely lack the tetraantennary class. Biantennary 
glycans were the largest glycan class present and this may have contributed to the faster 
migration of recombinant GH3-hFSH bands during SDS-PAGE. Nevertheless, the apparent 
greater abundance of hypo-glycosylated glycoform as compared with other pituitary and 
recombinant hFSH preparations indicated it was worthwhile to proceed to large-scale 
expression.
3.3 GH3-hFSH isolation
Large-scale GH3 cell expression of hFSH produced milligram quantities of immunoreactive 
recombinant hFSH in both serum-containing and serum-free conditioned media, which were 
processed separately. The following describes isolation of hFSH glycoforms from 10.4 liters 
of serum-free medium containing 21.2 mg hFSH immunoactivity. A total of 690 mg protein 
was eluted from Octyl-Sepharose with 30% ethanol. The FSH recovery was 95% of the 
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initial immunoreactivity. The dialyzed and lyophilized protein was dissolved in 0.1 M 
sodium phosphate, pH 7.0, with 0.15 M NaCl, and GH3-hFSH captured by immobilized 
anti-α monoclonal antibody 4882. GH3-hFSH and subunits were eluted from this resin with 
0.1 M glycine-HCl, 0.5 M NaCl buffer, pH 2.7. The recovery of recombinant GH3-
hFSH24/21 was 14.5 mg (68%) based on size exclusion chromatography (SEC) peak area. 
Separation of the FSH glycoforms was achieved by high performance gel filtration using 
three Superdex 75 columns connected in series. The resulting chromatogram consisted of a 
large heterodimer peak and a smaller free subunit peak (Fig. 3). Seven, 300 µL column 
fractions associated with the heterodimer peak were dried individually, dissolved in 600 µL 
water, the FSH concentration determined by SEC, and representative chromatograms shown 
(Fig. 3, inset I).
3.4 GH3-hFSH glycoform characterization
Each FSH and subunit fraction was evaluated by Western blot analysis (Fig. 3 inset II) and 
pooled glycoform preparations were characterized by SDS-PAGE (inset III). Comparison of 
the SEC chromatogram for fraction 1, at the beginning of the heterodimer peak, with that of 
fraction 7, near the end, revealed that the lower molecular weight fraction 7 exhibited a 
longer retention time and 71% increased peak width at half-height. The longer retention time 
indicated reduced molecular mass due, at least in part, to the absence of one or more FSHβ 
N-glycans, while greater peak width was consistent with the presence of two FSHβ bands in 
the Western blot of fraction 7 and only one in fraction 1. Similar results were obtained 
during analysis of fractions 2 and 6 (not shown). Carbohydrate composition analysis of 
fraction 1 and 2 hydrolysates indicated higher GlcNAc and Gal content relative to 3 Man 
residues than was found in fraction 6 and 7 hydrolysates (supplement Table 4). Greater 
relative abundance of both residues was consistent with fraction 1 and 2 glycans possessing 
largely triantennary glycans, which would possess 3 Gal residues/3 Man residues (actual 
values 2.9 and 2.8 for fractions 1 and 2, respectively). The Gal content of 1.4 residues/3 Man 
residues in fraction 6 and 7 hydrolysates suggests more 1- and 2-branch glycans, while the 
5.6 and 5.7 GlcNAc/3 Man content was consistent with initiation of the second and third 
glycan branches, but failure to extend them. Such glycans were detected in mass 
spectrometric analysis of total recombinant GH3-hFSH glycans (supplement Figs. 2 and 3). 
Sialic acid content was lower than the Gal content for all four hydrolysates indicating the 
presence of uncapped glycans, which were also observed in the glycan mass spectra. The 
same characteristics, enrichment for triantennary glycans in pituitary hFSH24 and greater 
abundance of biantennary glycans in hFSH21, along with partial sialylation of most glycans 
was observed following mass spectrometric analysis of pituitary hFSH glycoform glycans 
(Bousfield et al., 2014b).
FSH radioligand assay (Fig. 4A) indicated fractions 6 and 7 possessed the same receptor-
binding activity, which was 6.4-fold greater than that of fraction 2 and 15-fold greater than 
that of fraction 1 (Table 1). There was no significant difference between hFSH21/18 fractions 
6 and 7 (p = 0.37), but hFSH24 fraction 1 was significantly less active than fraction 2 (p < 
0.0001). Both low molecular weight hFSH21/18 fractions were significantly more active than 
both high molecular weight hFSH24 fractions (p < 0.0001).
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SDS-PAGE revealed a single, broad Coomassie Blue stained band for each glycoform 
preparation, which is typical for FSH preparations that display a high degree of 
microheterogeneity in the glycan moieties attached to both subunits (Fig. 3, inset III). The 
faster mobility of the broad GH3-hFSH21/18 band suggested both subunits were smaller than 
those associated with GH3-hFSH24. Three high molecular weight protein contaminants 
appeared in the hFSH24 lane, but were not observed in the SEC chromatogram (inset I), nor 
were they detected in Western blots.
Both glycoform preparations were analyzed by conventional, SDS-PAGE/electrotransfer to 
PVDF and probe, as well as automated, capillary electrophoresis Western blot procedures 
(Fig. 5). The pooled hFSH24 glycoform preparation possessed 79% FSHβ24 along with 21% 
FSHβ21 (Fig. 5A, lane 1). The latter was only 11% by automated Western blotting (Fig. 5B, 
lanes 3 and 4). The hFSH21/18 preparation appeared to possess a mixture of 54% FSHβ21 
and 46% FSHβ18 in the conventional blot and 66% and 34%, respectively, in the automated 
blot. The hFSHβ21 band partially overlapped with the FSHβ24 band in the hFSH24 
preparation in both Western blot systems. The GH3-hFSH21 fraction resembled pituitary 
hFSH21/18 isolated from hLH preparations, as both partially glycosylated FSHβ subunit 
variants were present (Bousfield et al., 2014a). It is likely the narrow detection range for our 
FSHβ Western blots was largely responsible for GH3-hFSH18 not being detected in the 
unfractionated GH3-hFSH. The difference in mobility between GH3-FSHβ24 and GH3-
FSHβ21 was not as large as expected from the individual fraction Western blot in Fig. 3.
Automated Western blot analysis involved separation of reduced samples by capillary 
electrophoresis under conditions that approximated 10% polyacrylamide gels, according to 
the manufacturer. Migration of FSH subunits differed from what we had become used to for 
conventional Western blots (Fig. 5B and C). Comparison with pituitary hFSH samples 
revealed GH3-hFSH24 β-subunit migrated as a single band, as in the conventional Western 
blot. While the separation of the GH3-hFSH21/18 bands was improved over polyacrylamide 
gels, migration of the FSHβ21 band was closer to that of the FSHβ24 band. Although the 
pituitary hFSH preparation possessed only FSHβ21, when subunits were immunopurified, its 
migration during capillary electrophoresis was like that of GH3-hFSH18. Migration of the 
FSHα subunits was similar for pituitary hFSH24/21 and GH3-hFSH24, which contrasted with 
the slower migration of FSHα in the GonalF and Follistim preparations in a conventional 
Western blot (Fig. 1, lanes 7–10). Migration of GH3-hFSH21/18 α-subunit produced a band 
as broad as pituitary FSHα, attended by a somewhat faster mobility.
3.5 Determination of glycosylation site occupancy by Edman degradation
In case of the hFSHβ24 there was virtually no PhNCS-Asn detected at cycles 5 and 7, which 
correspond to Asn7 in the truncated and full-length hFSHβ primary structures (supplement 
Figs. 6A and B). After PNGase F digestion, significant amounts of PhNCS-Asp were 
observed at Edman cycles corresponding to Asn7 in hFSHβ24 (supplement Figs. 6C and D). 
The results of sequencing PNGase F-digested hFSHβ21/18 demonstrated 23% of the Asn7 
and 71% of the Asn24 residues were not glycosylated (supplement Fig. 7). This was 
consistent with the greater abundance of hFSH21 (lacks Asn24 glycan) than hFSH18 (lacks 
Asn7 glycan) in GH3-hFSH21/18 Western blots.
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3.6 Comparison of GH3-hFSH glycoform receptor-binding activities
In a homologous competition assay, the activity of recombinant GH3-hFSH24 was 20844 
IU/mg, compared with highly purified pituitary hFSH reference preparation (Fig. 4B and 
Table 2). The activity of the recombinant GH3-hFSH21/18 preparation was 2.8-fold greater, 
57942 IU/mg. The reduced difference in the pooled glycoform preparation activities 
remained significantly different from each other (p < 0.0001) and from pituitary hFSH24 (p 
< 0.0001). It was unlikely that it was the use of human FSH tracer and hFSHR, as a 2-fold 
difference was observed in the rat/125 I-eFSH RLA for the same glycoform preparations 
(data not shown).
Leveling off of FSHR binding sites by both recombinant and pituitary hFSH24 tracer 
occurred at a lower concentration than that for GH3-hFSH21/18 tracer in three species, rat, 
bovine and human (Fig. 6). The difference in binding ranged from almost 2-fold in calf testis 
membranes to 3-fold in the CHO-hFSHR cell line (Table 3). An almost 6-fold difference 
was observed in the rat, however, this was due to the last 3 concentrations, which abruptly 
diverged from the pattern established by the first 6 concentrations (Fig. 6A inset). While not 
consistently observed in every experiment, this phenomenon occurs frequently.
3.7 Glycosyltransferase expression in GH3 cells
The majority of the glycans in GH3-hFSH were bi-antennary and these were more abundant 
than their counterparts in pituitary hFSH (supplement Fig. 2 and Table 2). A striking 
difference between pituitary and GH3 recombinant hFSH glycan populations was the 
absence of GlcNAc on the 4-position of the 3-antenna in tri-antennary glycans from the 
latter and the absence of GlcNAc on the 6-position of the 6-antenna in tri-antennary glycans 
from the former. As GlcNAc residues are attached to N-linked glycoproteins by specific 
GlcNAc transferases, we evaluated GH3 cell mRNA for GlcNAc transferase IV and V 
isozymes. The former adds GlcNAc in β1–4 linkage to Man α(1–3)Man in the 
pentasaccharide core, while the latter adds GlcNAcβ1–6 to Man α(1–6)Man. Since pituitary 
hFSH possesses tetra-antennary glycans, at least one isoform of each transferase must 
function in gonadotropes. Both GlcNAc transferase IVa and IVb, but not IVc, were 
expressed in GH3 cells, however, no GlcNAcβ(1–4)Man was detected in GH3-hFSH 
glycans. Only GlcNAc transferase V, but not Vb, was detected (Fig. 7A). The former 
appeared to be active as, all tri-antennary glycans possessed GlcNAcβ(1–6)Man. The 
abundance of tri-antennary glycans was much higher in pituitary hFSH glycans than in GH3-
hFSH glycans, suggesting the activity of GH3 GlcNAc transferase V was lower than that of 
pituitary GlcNAc transferase isozymes.
Antenna-linked Fuc residues were common in GH3-hFSH glycans and relatively rare in 
pituitary hFSH oligosaccharides (Green and Baenziger, 1988a, b, Renwick et al., 1987). 
GH3 cells expressed fucosyltransferase isozymes 1, 11, 10, 7, and 2, in decreasing order of 
PCR product abundance (Fig. 7B). The transferase isozyme responsible for antenna-linked 
fucose, Fut8, was undetectable in our experiments. Nevertheless GH3-hFSH glycans 
included more antenna-linked fucose than those derived from pituitary hFSH or hFSH 
glycoforms.
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In FSH, Neu5Ac is added in either α2–3 or α2–6 linkage. Each linkage is the result of a 
separate sialyltransferase isoform (Weinstein, de Souza-e-Silva and Paulson, 1982). RT PCR 
identified two α2–3 sialyltransferase isoform and one α2–6 sialyltransferase isoform 
messages (Fig. 7C). While no experiments were performed to evaluate the relative 
abundance of these two linkages, it is reasonable to expect more α2–3-linked Neu5Ac in 
GH3-hFSH preparations. This will be tested when additional recombinant GH3-hFSH 
glycoform preparations become available.
4. Discussion
The goal of the current study was to isolate and characterize recombinant FSH glycoforms. 
We found the three variants we are interested in studying: FSH24, FSH21, and FSH18. 
However, differences in electrophoretic mobility of the FSHβ bands required additional 
analysis to verify that GH3 cells had indeed produced all three. Oligosaccharide 
microheterogeneity differed from pituitary hFSH, revealing a shift toward more biantennary 
glycans and addition of a third antenna on a more flexible position, which might have 
affected electrophoretic mobility. The pooled recombinant glycoform preparations exhibited 
a reduced difference in apparent affinity for the FSH receptor and it is not yet known if this 
reflects cross contamination of glycoforms or variations in the ratio of FSH21 to FSH18. 
Furthermore, it is unknown if glycan structural differences from pituitary hFSH will be 
functionally significant. Results of both in vitro and in vivo functional studies using these 
recombinant glycoform analog preparations indicate that recombinant GH3-hFSH21/18 is 
more active than GH3-hFSH24 (Davis, J.S. and Kumar, T.R., unpublished data).
Mass spectrometry revealed many similarities and one major difference between pituitary 
hFSH and recombinant GH3-hFSH oligosaccharide populations. Comparison on the basis of 
individual glycan structures suggested greater similarity in glycosylation patterns for both 
preparations than when the combination of structures sharing the same neutral core were 
compared. For example, the three most abundant glycan structures in both hormone 
preparations were all disialylated biantennary oligosaccharides, while the fourth most 
abundant structures were trisialylated and triantennary, but differed in the location of the 
third antenna. This antenna was located on the Man6-branch in GH3-hFSH glycans, linked 
β1–6 to an exocyclic carbon atom in a mannose residue that was itself linked α1–6. The 
exocyclic linkages created the possibility of greater flexibility than is associated with 
triantennary pituitary FSH glycans, in which the third antenna was β1–4 linked to mannose 
ring carbon 4 in the Man3branch (Homans, Dwek and Rademacher, 1987). When glycan 
family abundance was compared, the greater abundance of triantennary glycans in pituitary 
hFSH was consistent with the fact that its two most abundant families both possessed 
triantennary glycan cores, as compared with biantennary cores for the two most abundant 
families in GH3-hFSH. For GH3-hFSH glycans, the third most abundant family was also 
biantennary, while only the fourth family was triantennary. The combination of smaller 
glycans and greater flexibility on the part of the GH3-hFSH triantennary glycans may have 
contributed to the faster electrophoretic mobility for this preparation than pituitary hFSH in 
Western blots.
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The purified GH3-hFSH Western blot revealed roughly equivalent amounts of hFSH24 and 
hFSH21, as compared with 20–27% hFSH21 in pituitary and other recombinant hFSH 
preparations. The promise of increased yield of hypo-glycosylated hFSH was fulfilled, as 
purification yielded twice as much GH3-hFSH21/18 as GH3-hFSH24. All three glycoforms 
were present in GH3-hFSH preparations, although hFSH18 was not detected until the 
glycoform separation step, as previously reported for pituitary hFSH glycoforms (Bousfield 
et al., 2014a). Differentiating GH3-hFSH21 from GH3-hFSH24 by either conventional or 
automated Western blot experiments was not straightforward because of partial overlap in 
electrophoretic mobilities of the FSHβ and FSHβ21 subunit bands. This may have been due 
to greater biantennary glycan abundance (56%) and reduced abundance of tri-antennary 
glycans (30%) in GH3-hFSH preparations than was observed in pituitary hFSH (38% and 
41%, respectively). However, Gonal F preparations appear to possess even more (66%) 
biantennary glycans, with only 24% triantennary and 9% tetraantennary (Gervais et al., 
2003), yet the electrophoretic mobilities of their β-subunits match those of pituitary hFSH. 
While glycans are generally considered to be very flexible molecules, one feature that 
exhibits the greatest flexibility is the antenna attached to the Man6-branch (Petrescu et al., 
1999). Since GH3-hFSH triantennary glycans almost exclusively possess Man6-linked third 
antennae, the increased flexibility may permit greater mobility during electrophoresis. 
Nevertheless, automated Edman degradation of the deglycosylated, hypo-glycosylated 
FSHβ21/18 preparation confirmed the presence of both mono-glycosylated β-subunits and the 
greater abundance of FSHβ21 as compared with FSHβ18.
While individual GH3-hFSH21/18 column fractions exhibited a 6- to 15-fold greater apparent 
affinity for the rat FSH receptor, the pooled GH3-hFSH21/18 preparation displayed only 2.8-
fold greater affinity for both the rat and human FSH receptors. The reduced difference was 
caused by a leftward shift of the GH3-hFSH24 ID50. It is possible that the 11–21% 
contamination with hypo-glycosylated hFSH, detected in Western blots, contributed to the 
increased receptor-binding activity of GH3-hFSH24. However, purified pituitary hFSH 
preparations often possess 20% hFSH21, yet are only as active as most hFSH24 preparations 
(Bousfield et al., 2014a, Bousfield et al., 2007). We were able to use 125I-hFSH21/18 to 
demonstrate that this glycoform could access at least twice as many FSH binding sites as 
hFSH24 tracer in FSH receptor-binding experiments involving two additional species, 
bovine and human. This is consistent with a recent report from our laboratory that during 
competitive binding and association assays, that used the same concentration of 125I-FSH 
tracer, or those experiments in which the tracer concentrations progressively increased, 
hypo-glycosylated pituitary FSH preparations bound more rat FSHR sites than fully-
glycosylated FSH24 preparations (Bousfield et al., 2014a). The magnitude of the binding in 
the present study reflected the increasing numbers of FSH receptors found in rat and calf 
testicular membranes and in overexpressed human FSH receptors. Nevertheless, greater 
hFSH21/18 binding was consistently observed, suggesting it is a general phenomenon.
When FSHRs were assumed to exist as single receptor molecules in target cell membranes, 
increased ligand binding associated with missing N-glycans would have been difficult to 
interpret because hFSH glycans do not appear to be close to the FSHR extracellular domain 
(supplement Fig. 8A). However, FSHR has been reported to exist as dimers, trimers or small 
oligomers in the membrane (Guan et al., 2010, Jiang et al., 2014, Thomas et al., 2007). 
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Accordingly, binding of FSH to one ligand binding site may affect FSH binding to a second 
ligand binding site, and dissociation studies seemed to provide supporting evidence (Urizar 
et al., 2005). Moreover, FSH dissociation was incomplete, supporting the existence of 
monomeric as well as dimeric/oligomeric receptors. As the latter possess one occupied and 
at least one unoccupied FSH binding site, unlabeled hormone may bind the unoccupied site 
and subsequently displace bound FSH tracer. Dimeric/oligomeric FSHRs account for the 
ability of 1000-fold excess cold FSH to partially displace receptor-bound 125I-FSH tracer. 
As monomeric FSH receptors lack unoccupied FSH binding sites, cold hormone cannot 
displace FSH tracer because the FSH-FSHR binding has been demonstrated to be stable for 
as long as 24 hours in the absence of cold FSH (Cheng, 1975). A recent review of FSH and 
FSHR structural biology pointed out that as FSH binding proceeds, the molecule exhibits 
less and less flexibility, which is consistent with the absence of spontaneous dissociation by 
FSH from its receptor (Jiang, Dias and He, 2013).
Qualitative differences in FSHR conformation or in the number of ligand binding sites 
occupied might alter signal transduction in gonadal target cells. Alternatively, it has been 
shown that some cellular responses to gonadotropin stimulation, such as cAMP 
accumulation, are directly proportional to the number of occupied receptors on the surface 
of target cells (Bhaskaran and Ascoli, 2005). The larger number of FSH binding sites 
available to hypo-glycosylated hFSH predicts that it will be more active than fully-
glycosylated hFSH. Indeed, we have found this to be true both in vitro and in vivo (Davis et 
al., 2014). Despite some variation in the appearance of their β-subunit bands in Western 
blotting experiments, it seems likely that the mechanism responsible for the difference in 
receptor binding between hFSH21/18 and hFSH24 is the same for both pituitary and 
recombinant FSH glycoform preparations.
A recent study characterized hFSH isoforms, classified as either di- or tetra-glycosylated 
hFSH glycoforms (and corresponding to hFSH21/18 and hFSH24 in the present study) in 
daily serum samples obtained from 79 healthy women during their menstrual cycles 
revealed very interesting observations (Wide and Eriksson, 2013). The pattern of the serum 
hFSH21 concentrations was characterized by a steep rise from day 27 of a previous cycle to 
days 3–6 of the next cycle and then a decrease in concentration lasting from day 7 to day 11 
followed by a pronounced midcycle peak (Wide and Eriksson, 2013). After that there was a 
rapid decrease to the lowest level on days 17–19 (Wide and Eriksson, 2013). The hFSH24 
glycoform concentration increased to a high plateau level lasting from day 3 to day 15 
followed by a slow decrease with no midcycle peak (Wide and Eriksson, 2013). These 
findings suggest that FSH glycoforms have different physiological roles in ovarian 
stimulation and are consistent with clinical studies showing improved ovarian stimulation 
with mixtures of acidic and less acidic hFSH isoforms (Selman, Pacchiarotti and El-
Danasouri, 2010). High and low sialic acid content FSH and Conanavalin A unbound and 
tightly bound FSH have recently been shown to elicit strikingly different patterns of gene 
expression in cultured KGN granulosa cell tumor cells (Loreti et al., 2013). The availability 
of recombinant hFSH glycoform preparations will make it possible to determine if similar 
effects can be obtained with fully- and hypo-glycosylated hFSH, as GH3-hFSH21/18 
Butnev et al. Page 11













glycoforms have been demonstrated to be more active than GH3-hFSH24 both in vitro and in 
vivo (Davis et al., 2014).
Transformed GH3 cells expressed the three physiologically relevant hFSH glycoforms, 
FSH24, FSH21, and FSH18, previously found in the pituitary gland. Glycan mass 
spectrometry revealed many of the glycan structures found in pituitary hFSH were also 
present in GH3-hFSH. Amino acid sequencing of the hypo-glycosylated glycoform β-
subunits revealed that the Asn24 oligosaccharide is missing from hFSH21 and the Asn7 
glycan is missing in hFSH18. Hypo-glycosylated hFSH21/18 preparations exhibited higher 
apparent affinity for the FSH receptor and occupied twice as many FSH binding sites as 
fully-glycosylated hFSH24.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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• Recombinant hFSH glycoforms hFSH24, hFSH21, and hFSH18 were expressed 
in transformed GH3 cells.
• Recombinant hFSH showed a similar pattern of glycosylation 
macroheterogeneity as pituitary hFSH.
• Oligosaccharide microheterogeneity was similar for both pituitary and 
recombinant hFSH, the major qualitative difference was the branching pattern 
for triantennary glycans.
• Recombinant hFSH21/18 occupied more FSH binding sites than pituitary hFSH24 
in binding assays involving rat, bovine, and recombinant human FSH receptor 
preparations.
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Figure 1. FSH subunit Western blot collage comparing several pituitary and recombinant hFSH 
glycoform preparations
Samples of reduced hFSH preparations were subjected to electrophoresis on 15% 
polyacrylamide gels, electroblotted to PVDF, and probed with anti-hFSHβ monoclonal 
antibody RFSH20 (upper panel) and anti-alpha antibody HT13 (lower panel). The arrows 
indicate the 24,000 and 21,000 Mr pituitary hFSHβ bands, as well as the FSHα subunit band. 
Lane 1, 1 µg pituitary hFSH AFP4161; lane 2, 1 µg GH3-hFSH; lane 3, 0.5 µg GH3-hFSH; 
lane 4, 1 µg hFSH AFP4161 (20% FSHβ21); lane 5, 1 µg pituitary hFSH21/18 (60% FSHβ21, 
40% FSHβ18); lane 6, 1 µg hFSH24 (FSHβ21 below limits of detection); lanes 7 and 8, 0.5 
and 1 µg samples Follistim recombinant hFSH (27% FSHβ21); lanes 9 and 10, 0.5 and 1 µg 
samples GonalF recombinant hFSH (21% FSHβ21). Lanes 1–3 and 4–10 are from separate 
Western blots.
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Figure 2. Comparison of pituitary hFSH with recombinant GH3-hFSH glycans
The mass spectra, data tables, and glycan structure diagrams are shown in the supplement. 
A. Glycan abundance based on neutral core oligosaccharide structures, as indicated. B. Six 
most abundant neutral glycan cores for pituitary and recombinant hFSH, as indicated. C. 
Glycan variant abundance, grouped by neutral core structure. D. Six most abundant glycans 
in pituitary and recombinant hFSH, as indicated.
Butnev et al. Page 17













Figure 3. Superdex 75 chromatography of immunopurified recombinant, GH3-hFSH
Representative chromatogram showing fractionation of hFSH heterodimer and subunit 
peaks. Fractions 1–3 were pooled, as indicated by shaded bar labeled, A, and yielded 514 µg 
GH3-hFSH24, while GH3-hFSH21/18 consisted of pooled fractions 6 and 7, which yielded 
1058 µg lyophilized protein (B). The intermediate molecular weight, mixed glycoform 
preparation consisted of 1106 µg. Total GH3-hFSH recovery was 2680 µg, 12.6% of the 
FSH immunoreactivity in conditioned medium. Inset II shows a collage of two Western 
blots used to identify the components of each fraction. The blots were aligned by the tops of 
the FSHβ24 bands in urinary hFSH24/21 used as a reference. The bar indicating the portion of 
the free subunit peak evaluated in this study was labeled C. Inset I: analytical SEC of 
fractions 1 and 7 illustrating the differences in peak shape and retention time. Inset II: Anti-
hFSHβ Western blot of fractions 1–14, as indicated. Inset III: SDS-PAGE followed by 
Coomassie Blue staining. Lane 1, GH3-hFSH24; lane 2, GH3-hFSH21/18. BioRad Precision 
Pre-stained MW marker positions are indicated.
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Figure 4. FSH radioligand assay of GH3-hFSH fractions and glycoform preparations
A. Samples of fractions 1, 2, 6, and 7 from the chromatogram in Fig. 3 were serially diluted 
and used to compete for the binding of 125I-eFSH to rat testis homogenate. Reference 
preparations included hFSH24/21 (AFP7298A, closed circle) and pituitary hFSH24 (closed 
square). Quantitative results are listed in Table 1. B. GH3-hFSH glycoform preparations 
tested in a homologous FSH RLA, which employed 125I-hFSH21 as tracer and CHO cells 
expressing hFSH receptors as the receptor preparation. Quantitative results are listed in 
Table 2.
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Figure 5. Conventional and automated Western blotting of GH3-hFSH
24 and –hFSH21/18 
preparations
A. Conventional Western blot probed with anti-hFSH/FSHβ antibody RFSH20. Lane 1, 1 µg 
GH3-hFSH24; lane 2, 1 µg GH3-hFSH21/18. B. Automated Western blot probed with anti-
FSHβ antibody 15-1.C3C5 diluted 1:100. Lane 1, 40 ng pituitary hFSH AFP7298A; lane 2, 
40 ng pituitary hFSH AFP7298A; lane 3, 40 ng GH3-hFSH24; lane 4, 40 ng GH3-hFSH24; 
lane 5, 40 ng GH3-hFSH21/18; lane 6, 40 ng GH3-hFSH21/18. C. Automated Western blot 
probed with anti-α antibody 15-2.C3.B8 diluted 1: 100. Samples are shown in the same 
order as in panel B.
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Figure 6. Binding of GH3-hFSH glycoforms to rat, bovine, and human FSH receptors under 
conditions close to saturation
Specific binding of 125I-GH3-hFSH24, 125I-pituitary hFSH24, or 125I-GH3-hFSH21/18, as 
indicated, to FSH receptor preparations. A. Rat testicular homogenate 25 mg/tube. Inset. 
Binding at low tracer concentrations. B. Calf testis membranes 20 mg/tube. C. Human FSH 
receptors expressed in Chinese hamster ovarian cells, 250,000 cells/tube. Each panel, 
representative results from two experiments.
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Figure 7. Glycosyltransferase expression in GH3 cells
A. RT-PCR detection of glycosyltransferases in GH3 cells expressing hFSH. B. 
Fucosyltransferase isoform expression in GH3 cells expressing hFSH. C. Sialyltransferase 
isoform expression in GH3 cells expressing hFSH.
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Table 1
FSH receptor-binding activities of GH3-hFSH glycoform fractions
Two high molecular weight and two low molecular weight fraction that were recovered from Superdex 75 gel 






Pituitary hFSH24/21 114 8560a
Pituitary hFSH24 253 3875
GH3-hFSH Frxn 1 131 7498 15.0
GH3-hFSH Frxn 2 56 17518 6.4
GH3-hFSH Frxn 6 7.9 124335
GH3-hFSH Frxn 7 8.7 112598
a
As provided by the National Hormone and Pituitary Program for AFP7298A.
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Table 2
FSH receptor-binding activities of GH3-hFSH glycoform preparations








Pituitary hFSH24/21 75 8560a
Pituitary hFSH24 136 4721
GH3-hFSH24 30.8 20844
GH3-hFSH21/18 11.1 57942 2.8
a
As provided by the National Hormone and Pituitary Program for AFP7298A.
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Table 3
Ratio of FSH21/18 to FSH24 binding to rat, bovine, and human FSH receptors in receptor binding studies under 
conditions close to saturation shown in Fig. 6.
FSH receptor preparation Rat Testis Homogenate Calf Testis Membranes CHO-hFSHR
FSH24 Bmax 0.9972 2.609 600.8
FSH24 Kd 1062 685.0 1805
FSH21/18 Bmax 5.859 4.721 1784
FSH21/18 Kd 4198 484.9 1697
Ratio FSH21/18/FSH24 Bmax 5.9 1.8 3.0
Mol Cell Endocrinol. Author manuscript; available in PMC 2016 April 15.
